Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
David Wisniewski(National Cancer Institute), Bayard D. Clarkson(Memorial Sloan Kettering Cancer Center), John Kuriyan(Vanderbilt University), Chongyuan Liu, A Strife, Matthew A. Young(Howard Hughes Medical Institute), Darren R. Veach, Bhushan Nagar(McGill University), Joseph R. Bertino(Rutgers, The State University of New Jersey), William G. Bornmann(Memorial Sloan Kettering Cancer Center), Thomas H. Schindler(University Hospital of Geneva), C Lambek
PubMed
August 1, 2002
Cited by 161